Volume | 36 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
EXACT Sciences Corporation | EXAS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
58.86 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
8 | 36 | - | 56.05 - 100.77 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
08:21:53 | 1 | $ 58.50 | USD |
EXACT Sciences (EXAS) Options Flow Summary
EXACT Sciences Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
10.68B | 181.53M | - | 2.58B | -204.15M | -1.12 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
EXACT Sciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EXAS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 60.73 | 61.59 | 57.48 | 59.28 | 1,734,766 | -1.87 | -3.08% |
1 Month | 59.82 | 63.74 | 56.05 | 59.21 | 2,186,972 | -0.96 | -1.60% |
3 Months | 74.66 | 77.42 | 56.05 | 63.38 | 1,894,372 | -15.80 | -21.16% |
6 Months | 74.96 | 77.42 | 56.05 | 64.46 | 1,742,038 | -16.10 | -21.48% |
1 Year | 63.39 | 100.77 | 56.05 | 72.43 | 1,690,172 | -4.53 | -7.15% |
3 Years | 129.00 | 140.18 | 29.27 | 69.85 | 1,871,395 | -70.14 | -54.37% |
5 Years | 92.48 | 159.54 | 29.27 | 81.45 | 1,876,315 | -33.62 | -36.35% |
EXACT Sciences Description
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in multi-cancer liquid biopsy cancer screening. |